On December 5th, 2022, Dr. Fu Dianxun and his team from the Department of Radiology at Tianjin Medical University General Hospital successfully performed a liver malignant solid tumor ablation surgery using the cutting-edge Nanoknife tumor ablation technology and CT guidance for a patient with liver metastasis after pancreatic cancer resection. The surgery was performed using the High Voltage Steep Pulse Minimally Invasive Therapeutic System independently developed and produced by Shanghai Yuanshan Medical Technology Co., Ltd. (hereinafter referred to as "Alpmed").

On July 5, 2022, Professor Ye Xin from the Minimally Invasive Oncology Department of Qianfoshan Hospital in Shandong Province led a team to successfully perform irreversible electric perforation ablation treatment on a patient with advanced malignant abdominal tumors. The "domestic nano-knife" used in the surgery was independently developed and produced by Alpmed - High Voltage Steep Pulse Minimally Invasive Therapeutic System.

Vice President Li Yongliang of Zigong High-tech Cancer Hospital personally received the patient and led the team to discuss the case multiple times. He also consulted with Professor Liao Zhengyin from the Interventional Center of West China Hospital of Sichuan University. After fully understanding the patient's condition, Professor Liao Zhengyin stated that the patient's condition was severe and the tumor was located in a special area near the hepatic portal vein. The cancer cells had invaded the surrounding tissues, posing great challenges to the surgical approach and the range of resection. The latest Nanoknife ablation therapy can achieve precise and selective ablation, with minimal impact on the blood vessels and bile ducts in the hepatic portal area. By releasing high-pressure pulses, it can cause apoptosis and necrosis of tumor cells. Percutaneous puncture is a minimally invasive method that is also very helpful for postoperative recovery of patients and can be attempted. Therefore, on June 19th, Professor Liao Zhengyin and Vice President Li Yongliang led the team to successfully perform Nanoknife ablation therapy for the patient under CT guidance. The "domestic Nanoknife" used in the surgery is the High Voltage Steep Pulse Minimally Invasive Therapeutic System independently developed and produced by Shanghai Yuanshan Medical Technology Co., Ltd.(Alpmed)

On March 17, 2022, Dr. Tan Yongcai's team from the Oncology Department of Jinshazhou Hospital of Guangzhou University of Chinese Medicine successfully completed liver malignant tumor ablation treatment for two patients using the latest Nanoknife tumor ablation technology guided by CT puncture. The surgery used the High Voltage Pulse Minimally Invasive Therapeutic System independently developed and produced by Shanghai Yuanshan Medical Technology Co., Ltd. (hereinafter referred to as "Alpmed").

Tianjin Medical University General Hospital, as a leading institution in medical technology and standardized management in Tianjin, not only takes the lead in fighting the epidemic prevention and control, but also ensures the normal medical treatment of patients. The interventional radiology team of the General Hospital has been working overtime to provide timely and efficient treatment plans for cancer patients in need.